{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.99","upperLimit":"4.83","value":"4.21"},{"groupId":"OG001","lowerLimit":"1.48","upperLimit":"2.60","value":"1.54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"173"}],"units":"Participants"}],"description":"The Progression-Free Survival (PFS) was assessed as median number of months from baseline until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. Independent Data Monitoring Committee performed ongoing safety monitoring and conducted the interim analysis after 189 death events and 329 PFS events were observed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Trabectedin at a dose of 1.5 milligram per meter square (mg/m\\^2) was given as an intravenous (IV) infusion over 24-hour every 3 weeks on Day 1 of every cycle (21 days) until disease progression. Dexamethasone 20 mg IV was also administered within 30 minutes before start of each trabectedin infusion.","id":"OG000","title":"Trabectedin"},{"description":"Dacarbazine at a dose of 1 gram per meter square (mg/m\\^2) was given as an intravenous (IV) infusion over 20-120 minutes every 3 weeks on Day 1 of every cycle (21 days) until disease progression. Dexamethasone 20 mg IV was also administered within 30 minutes before start of each dacarbazine infusion.","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants up to interim analysis cut-off date (16 September 2013). \"N\" (number of participants analyzed) signifies the participants evaluable for this measure.","reportingStatus":"POSTED","timeFrame":"approximately 2 years 4 months (From Study start date [27 May 2011] up to interim analysis data cut-off [16 September 2013])","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}